SynthesisAsian Pacific journal of cancer prevention : APJCP2025
Efficacy of Lenvatinib Versus Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pachymic acid exhibits synergistic antitumor efficacy with lenvatinib in hepatocellular carcinoma by targeting PPARγ to inhibit glycolysis.Medical oncology (Northwood, London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHepatocellular carcinoma (HCC) was the third leading cause of cancer-related deaths in the world. Current global treatment recommendations suggest lenvatinib and sorafenib have been approved to treat unresectable HCC. Studies comparing lenvatinib versus sorafenib for unresectable HCC have shown conflicting results and no structured review has yet evaluated its efficacy and safety. This article aims to estimate the efficacy of lenvatinib and sorafenib in patients with unresectable HCC.
methodsThis research was conducted using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) strategy. Literature searches were conducted through PubMed, ScienceDirect, Google Scholar, Cochrane Library, SpringerLink, and Ebsco. After quality assessment using the Newcastle-Ottawa Scale (NOS) and Cochrane Risk-of-bias, also data extraction, Review Manager 5.4 and RStudio 2024.04.1 software were used for analysis of overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR).
resultsA total of 9 studies were included, comprising 3,821 samples. All studies were retrospective studies. Our meta-analysis showed that OS and PFS in patients receiving lenvatinib were significantly better than patients receiving sorafenib with a protective hazard ratio (HR) of 0.70 (95%CI: 0.57-0.87, p=0.001) and 0.65 (95%CI: 0.54-0.78; p < 0.00001) respectively. Moreover, in the viral patients group, lenvatinib showed similar OS compared with sorafenib (HR=1.02; 95%CI: 0.77-1.36, p=0.87). Lenvatinib exhibited better ORR (OR = 7.87; 95%CI: 2.02-30.75; p = 0.003) and DCR (OR = 1.99; 95%CI: 1.53-2.60; p < 0.00001) compared with sorafenib.
conclusionLenvatinib provided significant benefits in OS, PFS, ORR, and DCR compared to sorafenib in patients with unresectable HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.